Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Tendera

Showing results (21-30 of 131) with videos related to

Pageof 14
Sort By:
European Journal of Heart Failure|November 21, 2008
The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trialChristian J F Holubarsch, Wilson S Colucci, Thomas Meinertz, et al.
Journal of Medical Internet Research|May 17, 2021
Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice TechnologyTomasz Jadczyk, Wojciech Wojakowski, Michal Tendera, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal|September 12, 2006
The perindopril in elderly people with chronic heart failure (PEP-CHF) studyJohn G F Cleland, Michal Tendera, Jerzy Adamus, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
International Journal of Cardiology|November 7, 2002
Age-adjustment of HRV measures and its prognostic value for risk assessment in patients late after myocardial infarctionMaciej Sosnowski, Peter W MacFarlane, Zbigniew Czyz, et al.
European Journal of Heart Failure|April 17, 2012
Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF studyJohn G F Cleland, Jacqueline Taylor, Nick Freemantle, et al.
Circulation. Cardiovascular Quality and Outcomes|December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life SubstudyMichal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
European Journal of Heart Failure|November 21, 2008
The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trialChristian J F Holubarsch, Wilson S Colucci, Thomas Meinertz, et al.
Journal of Medical Internet Research|May 17, 2021
Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice TechnologyTomasz Jadczyk, Wojciech Wojakowski, Michal Tendera, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal|September 12, 2006
The perindopril in elderly people with chronic heart failure (PEP-CHF) studyJohn G F Cleland, Michal Tendera, Jerzy Adamus, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
International Journal of Cardiology|November 7, 2002
Age-adjustment of HRV measures and its prognostic value for risk assessment in patients late after myocardial infarctionMaciej Sosnowski, Peter W MacFarlane, Zbigniew Czyz, et al.
European Journal of Heart Failure|April 17, 2012
Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF studyJohn G F Cleland, Jacqueline Taylor, Nick Freemantle, et al.
Circulation. Cardiovascular Quality and Outcomes|December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life SubstudyMichal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Pageof 14